Anti-Cancer Drug Design

Synthesis, structure and tumour necrosis factor‐α production‐enhancing properties of novel adamantylamino heterocyclic derivatives
pp. 73-80(8)
Authors: Maurin1,2, Jan Krzysztof; Lasek3, Witold; Górska4, Agata; Świtaj3, Tomasz; Wamil3, Małgorzata; Młynarczuk3, Izabela

The interaction of DNA‐targeted platinum phenanthridinium complexes with DNA in human cells
pp. 81-89(9)
Authors: Whittaker, Joanne; McFadyen1, W. David; Baguley2, Bruce C.

Synthesis, cytotoxicity, cell uptake and DNA interstrand cross‐linking of 4,4′‐dipyrazolylmethane‐linked multinuclear platinum anti‐cancer complexes
pp. 91-98(8)
Authors: Wheate, Nial J.; Cullinane1, Carleen; Webster1, Lorraine K.

DNA binding properties of the indolocarbazole antitumor drug NB‐506
pp. 99-107(9)
Authors: Carrasco, Carolina; Vezin1, Hervé; Wilson2, W. David; Ren3, Jinsong; Chaires3, Jonathan B.

New cytotoxic analogues of annonaceous acetogenins
pp. 109-117(9)
Authors: Rodier, Stéphane; Huérou1, Yvan Le; Renoux, Brigitte; Doyon1, Julien; Renard2, Pierre; Pierré3, Alain; Gesson, Jean‐Pierre

Investigations on the biological properties of the lipophilic DHFR‐inhibitory benzoprims reveal non‐folate modes of action and opportunities for anti‐cancer drug design
pp. 119-128(10)
Authors: Croughton, Karen A.; Matthews, Charles S.; Griffin1, Roger J.

Identification of a novel steroid derivative, NSC12983, as a paclitaxel‐like tubulin assembly promoter by 3‐D virtual screening
pp. 129-133(5)
Authors: Wu1,2, Jian Hui; Batist2, Gerald

Nuclear and mitochondrial distribution of organoamidoplatinum(II) lesions in cisplatin‐sensitive and ‐resistant adenocarcinoma cells
pp. 135-141(7)
Authors: Talarico1,2, Teresa; Cullinane2, Carleen M; Gray3, Peter J; Webster2, Lorraine K.; Deacon4, Glen B.

The role of ring D in the antitumour antibiotic streptonigrin: metal complexation, DNA binding and topoisomerase inhibition by ABC ring analogues of streptonigrin
pp. 143-153(11)
Author: Anderberg, Pia I.

The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin‐1, has unique bioactivity independent of protein kinase C
pp. 155-166(12)
Authors: Hood1, Kylie A.; Bäckström2, B. Thomas; West3,4, Lyndon M.; Northcote3, Peter T.; Berridge2, Michael V.

Synthesis and antitumor activity of substituted 3‐(5‐imidazo[2,1‐b]thiazolylmethylene)‐2‐indolinones
pp. 167-174(8)
Authors: Andreani, Aldo; Granaiola, Massimiliano; Leoni, Alberto; Locatelli, Alessandra; Morigi, Rita; Rambaldi, Mirella; Giorgi1, Gianluca; Salvini1, Laura